Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Lean Rx vs MadeMed

By GLP-1 ScorecardUpdated

Lean Rx
Site position #362

Lower grade

MadeMed
Site position #23

Higher grade

Score comparison

MadeMed has the higher recorded score — 80.4/100 to 60.6/100.

MadeMed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MadeMed advertises all-dose pricing across 30-, 90- and 360-day purchases, with a consultation-fee conflict to resolve before prepaying.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueMadeMed +34
40
74
Dose & formulationMadeMed +15
75
90
Clinical oversightMadeMed +3
81
84
Labs & monitoringMadeMed +10
52
62
FulfillmentMadeMed +30
60
90
Contract termsMadeMed +33
55
88
Lean Rx · top barMadeMed · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricLean RxMadeMed
WeighScore60.6/10080.4/100
GradeCB−
Site position#362#23
Semaglutide$266/mo (starting dose, compounded)$179 every 30 days; $483/90 days or $1,718/360 days ($143.17 equivalent per 30 days); consultation fees and usable supply require confirmation
Tirzepatide$399/mo (starting dose, compounded)Injection or sublingual: $249 every 30 days; $672/90 days or $2,390/360 days ($199.17 equivalent per 30 days); final fees and supply unverified
CoverageCoverage not publishedConfirm selected treatment/state: sublingual tirzepatide FAQ lists 40 states; current injection-state map unverified
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesYes
Lean Rx

Site position #362 · C

Strengths

  • Both semaglutide and tirzepatide offered
  • Three formulations: injectable, sublingual, and tablet
  • Upfront pricing with no hidden fees advertised
  • Semaglutide starts at a low $266/month
  • Telehealth call with a licensed provider before prescribing

What to consider

  • Compounded-only; no FDA-approved branded options
  • No published state availability list
  • Platform is technology only, not a healthcare provider itself
  • Provider credentials not detailed on site
MadeMed

Site position #23 · B−

Strengths

  • Public selectors show full charges for 30-, 90- and 360-day plans across the listed GLP-1 products
  • Advertises the same pricing across doses, ongoing clinical messaging and included injection supplies
  • Current terms name MDI Medical Group PC and four partner pharmacy brands
  • A 30-day purchase is advertised alongside the larger prepaid options

What to consider

  • Lowest advertised equivalents require $1,718/$2,390 360-day billing plans; terms reject prorated refunds
  • Product pages list $20/$30 consultation fees while How It Works says consultation is included and ineligible payments are refunded in full
  • The forty-state claim is specific to sublingual tirzepatide; an injection-state map was not established
  • Assigned clinician/pharmacy branch, patient lab costs, final first debit and usable prescription supply remain unresolved

Featured provider

MadeMed

MadeMed scores 80.4/100 (B−). MadeMed advertises all-dose pricing across 30-, 90- and 360-day purchases, with a consultation-fee conflict to resolve before prepaying.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard